China FDA Urged To Reduce IND Timeline To 30 Days
This article was originally published in PharmAsia News
Executive Summary
A Tsinghua University report commissioned by PhRMA sheds light on China’s lagging pharmaceutical regulatory legal system and calls for a rapid reform of the Drug Administration Law.